氯米帕明治疗难治性持续性生殖器觉醒障碍的试验：病例系列。
Clomipramine trial for treatment-resistant persistent genital arousal disorder: a case series.
机构信息
a Department of Psychiatry , Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Psychotherapy Outpatient Clinic , Istanbul , Turkey.
b Department of Psychiatry , Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery , Istanbul , Turkey.
出版信息
J Psychosom Obstet Gynaecol. 2017 Dec;38(4):260-267. doi: 10.1080/0167482X.2017.1296427. Epub 2017 Mar 3.
INTRODUCTION
Treatment of persistent genital arousal disorder (PGAD), as a chronic and disabling condition, implicates substantial compelling complexities.
METHODS
In this case series, seven women diagnosed with PGAD who were referred to the Sexual Dysfunction Unit of Psychotherapy Outpatient Clinic of Bakirkoy Research and Training Hospital for Psychiatry, Neurology, and Neurosurgery, Istanbul, Turkey between 2006 and 2009 were included. All patients were previously resistant to other antidepressants, antipsychotics and antiepileptics. The additional details of PGAD onset, frequency, type and duration of arousal, previous pharmacological interventions, and maximum and maintenance doses of clomipramine were recorded.
RESULTS
All patients achieved a substantial symptomatic improvement with clomipramine within the follow-up period of 2-9 years.
DISCUSSION
Based on our study results, we recommend clomipramine in combination with psychotherapy as the treatment of choice in PGAD and to be used before any invasive procedure such as electroconvulsive therapy (ECT) or surgery.
简介
持续性生殖器唤醒障碍（PGAD）作为一种慢性且使人致残的疾病，其治疗涉及到许多复杂问题。
方法
本病例系列研究纳入了 2006 年至 2009 年间土耳其伊斯坦布尔 Bakirkoy 精神病学、神经病学和神经外科研究和培训医院心理治疗门诊性机能障碍科转介来的 7 名被诊断为 PGAD 的女性患者。所有患者先前对其他抗抑郁药、抗精神病药和抗癫痫药均有抵抗。记录了 PGAD 发作的其他详细信息、唤醒的频率、类型和持续时间、先前的药物干预以及氯米帕明的最大和维持剂量。
结果
在 2-9 年的随访期间，所有患者的症状均因氯米帕明而得到显著改善。
讨论
根据我们的研究结果，我们建议在任何侵入性治疗（如电惊厥治疗或手术）之前，将氯米帕明联合心理治疗作为 PGAD 的治疗选择。
Zotero 插件